Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Ophthalmologists (US)

Analysis of: Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 (www.pipelinereview.com)
ALTY-0501 is new medication being used in the Dry Eye Market.  This reports reveals positive results from a Phase 2 Study.  It is exciting as there are limited products for treating Dry Eye; and this could be a new rival from Restatisis (Allergan; AGN).
Analysis of: Antioxidants Don't Prevent Macular Degeneration (www.medpagetoday.com)
An extensive meta-analysis by Wong et al involving a 149,203 patients shows that antioxidants do not prevent early macular degeneration (the formation of drusen.)  However, it does not refute the role of antioxidants in preventing wet or advanced macular degeneration (AMD). ...
Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye (www.nytimes.com)
Genetech (DNA) is looking to curb the off label use of its oncology medications (Avastin) in order to boost Lucentis sales.  It is a terrible PR move for the company that exposes its greed and bumbling moves but a good fianancial decision to maximize its profits for Lucentis. 
Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye (www.nytimes.com)
       Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label.   Although this amount of sales places Lucentis well within the blockbuster...
Analysis of: Inspire Completes Enrollment in Phase 3 Cystic Fibrosis Trial (www.pipelinereview.com)
Inspire Pharmaceuticals' founding concept is based upon P2Y2 receptor agonist technology, now approaching fruition with groundbreaking cystic fibrosis (CF) clinicals.  Well tolerated three times daily nebulizer therapy with denufosol for young CF patients promises improved pulmonary function,...
Analysis of: Microsoft launches Web site to hold medical records (uk.reuters.com)
This move by Microsoft has brought attention to a vast untapped field of personal medical information being saved online. It promises the convenience factor as well as privacy sought after by the patients. Making its foray into this field with two well thought acquisitions by Microsoft, this website...
Analysis of: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth (www.pnas.org)
Omega-3 supplementation could be a useful strategy for protecting against retinopathy of prematurity (ROP), say Swedish investigators. In the study, mice with retinopathy were fed food enriched with either omega-3 or omega-6. Mice that ate omega-3 initially lost fewer retinal blood vessels than mice...
Analysis of: Blood Pressure, Arterial Stiffness, & Open Angle Glaucoma: The Rotterdam Study (archopht.ama-assn.org)
Patients with high arterial pulse pressure may be at increased risk for high-tension open angle glaucoma, a Dutch study concludes. Researchers analyzed data from 5,317 individuals, 215 of who had definite or probable open-angle glaucoma and 5,102 of whom were disease free.The analysis found that high-tension...
Analysis of: Ophthalmic business: Alcon exceeds 70% stake in WaveLight (www.osnsupersite.com)
Alcon holds more than 70% of Wavelights shares and its takeover of Wavelight has been approved by the German authorities. WHile wavelight produces some interesting intraocular lenses, it is clear that Alcons interest in Wavelight lies in its realiable and fast excimer laser system that can be used for...
Analysis of: Targeting amyloid- b in Glaucoma (www.pnas.org)
New research indicating the presence of amyloid-beta protein in dying retinal cells  suggests a new direction in glaucoma research. Amyloid-beta is a protein found in Alzheimer's plaques. Using a rat model of glaucoma, the researchers found that the dying retinal cells showed accumulation of amyloid-beta....

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 146

Analytics


Generated at 2009-01-07T19:00:58.307